Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.63.00 CHF
Change Today 0.00 / 0.00%
Volume 0.0
BAX On Other Exchanges
New York
SIX Swiss Ex
As of 2:59 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

baxter international inc (BAX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/5/15 - SFr.69.20
52 Week Low
02/20/15 - SFr.63.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

baxter international inc (BAX) Related Businessweek News

View More BusinessWeek News

baxter international inc (BAX) Details

Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company’s BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; and biosurgery products. The Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; and products and services related to pharmacy compounding, drug formulation and packaging technologies, as well as to treat renal disease, irreversible kidney failures, and other renal therapies. This segment also offers products for peritoneal dialysis, in-center and home hemodialysis, continuous renal replacement therapy, and other dialysis services. It markets its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and patients. The company operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. It has collaboration with Merrimack Pharmaceuticals, Inc. to develop and commercialize MM-398 injection; CTI BioPharma Corp. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products; and Onconova Therapeutics, Inc. for rigosertib anti-cancer compound. The company was founded in 1931 and is based in Deerfield, Illinois.

66,000 Employees
Last Reported Date: 02/26/15
Founded in 1931

baxter international inc (BAX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $755.0K
Corporate Vice President and President of Bio...
Total Annual Compensation: $833.8K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $651.0K
Corporate Vice President of Human Resources
Total Annual Compensation: $525.3K
Compensation as of Fiscal Year 2014.

baxter international inc (BAX) Key Developments

CTI BioPharma Corp. and Baxter International's Bioscience Business Announce Data from Persist-1 Randomized Phase 3

CTI BioPharma Corp. and Baxter International's Bioscience business announced data from PERSIST-1 a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29-June 2, 2015 in Chicago, Ill. Pacritinib is an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3. Data presented at ASCO (Abstract #LBA7006) show that compared to best available therapy (exclusive of a JAK inhibitor), pacritinib therapy resulted in a significantly higher proportion of patients with spleen volume reduction and control of disease-related symptoms. Data were also selected for inclusion in the official ASCO Press Program. Myelofibrosis is associated with significantly reduced quality of life and shortened survival. Spleen enlargement (splenomegaly) is a common and debilitating symptom of myelofibrosis. As the disease progresses, the body slows production of important blood cells and within one year of diagnosis the incidence of disease-related thrombocytopenia (very low blood platelet counts), severe anemia, and red blood cell transfusion requirements increase significantly.

Baxter International Inc. Presents Data Demonstrating Remote Technology

Baxter International Inc. presented data showing how innovative dialysis systems with new remote connectivity may improve patient access to home therapy. The data, presented at the 52ndCongress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), includes the perceptions of more than 500 healthcare providers and patients regarding the benefits associated with advanced automated peritoneal dialysis (APD) cyclers with remote monitoring capabilities of home patients (Abstract # FP586), and several abstracts supporting cost-effectiveness and utility of High Dose Hemodialysis (HD). Home therapy is an important and often underutilized dialysis option. Globally, approximately 13% of dialysis patients are on home dialysis therapy, with the remaining patients on in-center treatment. The APD cycler study reported on results of phone and web-based surveys with patients, nephrologists and renal nurses in the United Kingdom and the United States to gauge the importance and utility of a cycler with remote monitoring features compared with a cycler without remote monitoring capability. Of those surveyed, 86 percent of the healthcare providers agreed an APD cycler with remote patient monitoring capabilities will provide them more confidence and control when managing peritoneal dialysis (PD) patients. Patients also felt the new APD cycler may help reduce operator errors due to the user interface. An additional study on the accessibility of home renal therapy included an analysis of the estimated cost-effectiveness attributable to High Dose HD. Because High Dose HD is performed more frequently, it is not typically performed in a clinic due to the high cost to administer. In an analysis of High Dose HD completed in the United Kingdom, Netherlands and France, High Dose HD at home was found to be cost-effective when compared to conventional in-center HD (ICHD) with the current reimbursement levels. However, High Dose HD when performed in-center versus ICHD was not cost-effective in France or the UK. This analysis also shows reimbursement could be raised to compensate providers for the increased costs and still maintain the efficiency to the relevant healthcare systems (Abstract #FP728). Baxter recently completed CE marking (market approval) and unveiled the HOMECHOICE CLARIA APD system with SHARESOURCE at ERA-EDTA. SHARESOURCE, a remote monitoring system that allows healthcare professionals to deliver individualized patient care at home, is also available on the VIVIA hemodialysis system. The VIVIA hemodialysis system, designed to deliver High Dose HD therapy in the home, also completed the CE marking process in Europe in 2013. HOMECHOICE CLARIA, SHARESOURCE (web-based remote monitoring system) and the VIVIA system are currently not available in the United States.

Baxter International Inc.'s BioScience Business Files for European Approval of Investigational 20% Subcutaneous Immune Globulin Treatment for Primary Immunodeficiency

Baxter International Inc. announced that its BioScience business has submitted a marketing authorization application (MAA) to 17 competent authorities in Europe following the decentralized procedure (DCP) for approval of its investigational 20% concentration subcutaneous immune globulin (IGSC) treatment for primary immunodeficiencies (PI, a group of disorders in which part of the body's immune system is missing or does not function properly). Baxter is advancing the 20% treatment as part of its efforts to expand the primary immunodeficiency treatment portfolio to address patient needs. The filing is based on the positive results of a Phase 2/3 study that evaluated the efficacy, safety, tolerability and pharmacokinetics (PK) of IGSC 20% in European patients at least two years old with PI. The study met its primary endpoint that measured the rate of validated acute serious bacterial infections (VASBIs); these results were initially presented during the 2014 biennial congress of the European Society for Immunodeficiencies (ESID).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BAX:SW SFr.63.00 CHF 0.00

BAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fresenius SE & Co KGaA €57.17 EUR -1.04
Kimberly-Clark Corp $108.37 USD -0.78
Mylan NV $72.28 USD -1.04
Stryker Corp $96.11 USD -0.01
Takeda Pharmaceutical Co Ltd ¥5,995 JPY -32.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BAX Industry Range
Price/Earnings 19.5x
Price/Sales 2.2x
Price/Book 5.0x
Price/Cash Flow 15.2x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BAXTER INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at